



**DEVELOPMENT AND ASSESSMENT OF NOVEL  
VACCINATION STRATEGIES FOR HEPATITIS B VIRUS  
INFECTION**

**Devin TEOH**

**(Chee Quin TEOH)**

**B.Sc. (Biotechnology), B.Sc. (Hons)**

A thesis submitted to the University of Adelaide  
in fulfilment of the requirements for the degree of Doctor of Philosophy

**Discipline of Microbiology and Immunology**

**School of Molecular and Biomedical Science**

**The University of Adelaide**

**South Australia**

**Australia**

November 2014

**To my loving family**

for your boundless love, care, support and always being there for me

**&**

**To Jean Ang**

who stood by me when things looked bleak and supported me each step of the way

# **Table of Contents**

<b>Abstract</b> -----	i
<b>Declaration of originality and consent</b> -----	v
<b>Publications and presentations resulting from this thesis</b> -----	vi
<b>Acknowledgements</b> -----	ix
<b>Abbreviations</b> -----	xi

## **Chapter 1 Introduction**

1.1	Background: Epidemiology of HBV infection-----	1
1.2	Hepadnaviruses-----	2
1.2.1	Hepadnavirus Family-----	2
1.2.2	B virus structure and genome organisation-----	2
1.2.3	Duck hepatitis B virus structure and genome organisation-----	9
1.3	Hepadnavirus Replication-----	10
1.3.1	Viral entry, transcription and translation to generate new virus-----	10
1.3.2	An important reservoir of hepadnavirus infection – cccDNA-----	13
1.4	Outcomes of HBV infection-----	13
1.4.1	Acute HBV infection-----	17
1.4.1.1	Resolution of acute HBV infection-----	17
1.4.2	Chronic HBV infection-----	20
1.5	Animal Model – Duck hepatitis B virus-----	23
1.6	Outcomes of DHBV infection -----	23
1.6.1	Acute DHBV infection -----	25
1.6.2	Persistent DHBV infection-----	25
1.6.3	CMI responses to DHBV infection -----	25
1.7	Treatment of HBV infection -----	27
1.7.1	Immunomodulators-----	27
1.7.2	Antiviral agents-----	28
1.7.2.1	Entecavir-----	29
1.7.2.2	Antiviral resistance to Nucleotide/nucleoside analogues-----	30
1.8	Hepadnavirus vaccines-----	31
1.8.1	The prophylactic HBV vaccines-----	31
1.8.2	DNA vaccines-----	32
1.8.2.1	Mechanism of antigen presentation following DNA vaccination-----	34
1.8.2.2	Enhancement of immunogenicity of DNA vaccines-----	35
1.8.2.3	Costimulatory molecules as genetic adjuvants -----	36
1.8.2.4	The co-stimulatory molecule CD40L-----	38
1.8.2.5	Current hepadnaviral vaccine studies-----	42
1.9	Poxviruses -----	43
1.9.1	Family Poxviridae-----	43
1.9.2	Structure and genome of Avipoxviruses-----	43
1.9.3	Replication of Avipoxviruses-----	44
1.9.4	FPV as vaccine vectors-----	45
1.9.5	Poxvirus vaccine developed to treat hepadnavirus infection-----	46
1.10	Research aims and study outline-----	47

## Chapter 2 Materials and Methods

2.1	Experimental animals-----	50
2.2	Cell culture-----	50
2.2.1	Preparation of primary duck embryonic fibroblasts (PDEF)-----	50
2.2.2	Collection and purification of duck peripheral blood mononuclear cells (PBMC)-----	51
2.2.3	Cell culture and PHA and ConA stimulation of spleen cells-----	51
2.2.4	Culture of 293T, LMH and PDEF cells-----	53
2.2.5	Cell transfection-----	53
2.2.6	Detection of DHBV antigens using Immuno-fluorescence (IMF) assay-----	54
2.2.7	Detection of DHBV antigens using western blot-----	55
2.3	Production of polyclonal and mAB to recombinant DHBV core antigen (rDHBcAg)-----	60
2.3.1	Preparation of rDHBcAg particles-----	60
2.3.1.1	Growth and transformed E.coli strains and partial purification of rDHBcAg particles-----	60
2.3.1.2	Separation and isolation of rDHBcAg particles by caesium chloride isopycnic density gradient centrifugation-----	61
2.3.1.3	Detection of rDHBcAg particles by ELISA-----	62
2.3.1.4	Precipitation of rDHBcAg using trichloroacetic acid (TCA)-----	63
2.3.1.5	To concentrate rDHBcAg particles and to determine the concentration of rDHBcAg particles -----	63
2.3.2	Production of polyclonal rabbit antibodies to rDHBcAg-----	64
2.3.2.1	Testing antibody responses by ELISA following immunisation with rDHBcAg-----	64
2.3.2.2	Absorption of polyclonal antisera with normal duck liver (NDL) and NDS---	65
2.3.3	Production of mABs to rDHBcAg-----	65
2.3.3.1	Hybridoma production -----	66
2.3.3.2	Hybridoma screening for anti-DHBC antibodies -----	69
2.4	Procedure involving Duck CD40L (DuCD40L) -----	69
2.4.1	Sub cloning of DuCD40L gene into pcSNA3 expression vector-----	69
2.4.1.1	Plasmid vector and primer design-----	69
2.4.1.2	RNA extraction-----	70
2.4.1.3	The cDNA synthesis and cloning by PCR-----	70
2.4.1.4	Restriction Endonuclease (RE) digestion-----	72
2.4.1.5	Ligation-----	72
2.4.1.6	Transformation-----	73
2.4.1.7	Preparation of plasmid DNA-----	73
2.4.2	Nitrate assay-----	74
2.4.3	Statistical analysis-----	75
2.4.4	Quantitative reverse transcription PCR (qRT-PCR) to detect iNOS mRNA---	75
2.5	Procedures involving ducks-----	75
2.5.1	DHBV stock and intravenous inoculation of ducks-----	75
2.5.2	DHBV vaccine and vaccination protocol-----	76
2.5.2.1	DNA vaccine-----	76
2.5.2.2	Vaccination protocols-----	77
2.5.3	Administration of antiviral drugs-----	77
2.5.4	Venipuncture-----	78
2.5.5	Liver Biopsy-----	78
2.5.6	Autopsy-----	79
2.5.7	Tissue fixation, embedding and sectioning-----	79
2.6	Serological Assays -----	79
2.6.1	Quantitative detection of DHBsAg by ELISA-----	80
2.6.2	Quantitative detection of anti-DHBs antibodies by ELISA -----	80

2.6.3	Detection of anti-DHBc antibodies by ELISA-----	81
2.7	Histology and immuno-staining of tissue sections-----	82
2.7.1	Immuno-staining to detect DHBsAg-----	82
2.7.2	Immuno-staining to detect DHBcAg-----	83
2.7.2.1	Microwave mediated antigen retrieval-----	83
2.7.2.2	Immunostaining detection of DHBcAg in liver tissue sections-----	83
2.8	Methods for extracting and detecting viral and cellular DNA-----	85
2.8.1	DNA extraction from serum for qPCR-----	85
2.8.2	DNA extraction from liver tissues for qPCR-----	85
2.8.3	Quantitation of DNA by qPCR-----	86
2.8.4	Detection of DHBV DNA in serum by qPCR-----	87
2.8.5	Detection of DHBV DNA in liver tissue by qPCR -----	87
2.9	Statistical analysis -----	88

### **Chapter 3 Production of polyclonal and monoclonal antibodies specific for DHBcAg**

3.1	Background-----	90
3.2	Purification of rDHBcAg particles expressed in <i>E. coli</i> -----	91
3.2.1	Preparation and purification of rDHBcAg-----	91
3.2.2	Separation and isolation of rDHBcAg particles by caesium chloride density gradient centrifugation-----	93
3.2.3	Detection of rDHBcAg particles by ELISA-----	94
3.2.4	SDS-PAGE and Western Blot analysis of the purity of rDHBcAg particles---	94
3.3	Production of polyclonal anti-DHBc antibodies-----	99
3.3.1	Immunisation of rabbits to generate polyclonal anti-DHBc antibodies-----	99
3.3.2	Optimisation of the use of polyclonal anti-DHBc antibodies (CQT-1 and CQT-2)-----	100
3.3.2.1	IMF staining of DHBcAg in tet-induced dstet5 cells using polyclonal anti-DHBc antibodies (CQT-1 and CQT-2)-----	100
3.3.2.2	Western Blot using polyclonal anti-DHBc antibodies (CQT-1 and CQT-2)-----	101
3.3.2.3	Detection of DHBcAg-positive hepatocytes in liver tissue sections-----	107
3.3.2.4	Comparison of the sensitivity in detection of DHBsAg- and DHBcAg-positive hepatocytes on liver tissue sections-----	111
3.4	Production of monoclonal anti-DHBc antibodies-----	118
3.4.1	Immunisation of mice and initial identification of hybridomas producing specific anti-DHBc antibodies -----	118
3.4.1.1	Western Blot screening of hybridomas producing anti-DHBc antibodies----	122
3.4.2	Optimisation of monoclonal anti-DHBc antibodies (5B-11F) -----	124
3.4.2.1	Western Blot analysis using anti-DHBc mABs (5B-11F) -----	126
3.4.2.2	Detection of DHBcAg-positive hepatocytes on liver tissue using mABs----	131
3.5	Expression of the DHBV DNA vaccines <i>in vitro</i> -----	131
3.6	Discussion -----	142

### **Chapter 4 Duck CD40 ligand (DuCD40L) DNA construct as a genetic adjuvant for DHBV DNA vaccines**

4.1	Introduction and aims-----	147
4.2	Experimental design-----	150
4.2.1	Experimental design of <i>in vivo</i> studies-----	150
4.3	<i>In vitro</i> Results-----	153
4.3.1	Isolation and Sequence Analysis of DuCD40L-----	153
4.3.2	Confirmation of DuCD40L protein expression by Western Blot detection in LMH cells transfected with pcDuCD40L-----	155

4.3.3	DuCD40L induced Nitric Oxide (NO) production in HD11 cells which was accompanied by inducible nitric oxide synthase (iNOS) gene upregulation-----	157
4.4	<i>In vivo</i> Results-----	165
4.4.1	Experimental I-----	165
4.4.1.1	Group 4A: The protective efficacy of DHBV DNA vaccines co-administrated with pcDuCD40L on DHBV challenge in 42-day-old ducks-----	165
4.4.1.2	Group 4B: The protective efficacy of DHBV DNA vaccines on DHBV challenge in 42-day-old ducks -----	184
4.4.1.3	Group 4C: The protective efficacy of pcDuCD40L on DHBV challenge in 42-day-old ducks-----	188
4.4.1.4	Group 4D: The pcDNA3 vector control ducks-----	190
4.4.2	Experiment II-----	191
4.4.2.1	Group 4E: The protective efficacy of pcDuCD40L on DHBV challenge in 42-day-old ducks-----	191
4.4.2.2	Group 4F: The pcDNA3 vector control ducks-----	200
4.5	Discussion-----	201

**Chapter 5 The protective efficacy of DuCD40L expression construct in combination with DHBV DNA vaccines in 14-day-old ducks**

5.1	Introduction and aims-----	207
5.2	Experimental design-----	211
5.3	Results -----	212
5.3.1	Group 5A: DHBV DNA vaccines expressing DHBV S in combination with DuCD40L expression constructs-----	212
5.3.2	Group 5B: DHBV DNA vaccines expressing DHBV Pre-S/S in combination with DuCD40L expression construct-----	221
5.3.3	Group 5C: DHBV DNA vaccines expressing DHBV S-----	227
5.3.4	Group 5D: DHBV DNA vaccines expressing DHBV Pre-S/S-----	228
5.3.5	Group 5E: DuCD40L expression construct alone-----	229
5.3.6	Group 5F: The pcDNA3 vector alone-----	233
5.4	Discussion-----	235

**Chapter 6 The development of persistent DHBV infection can be prevented using antiviral ETV therapy combined with “prime-boost” vaccination with either DHBV surface or core antigens**

6.1	Introduction and aims-----	244
6.2	Experimental design-----	250
6.3	Results-----	251
6.3.1	Group A: DHBV infection outcomes in ducks received ETV treatment in combination of “prime-boost” vaccines that expressed surface and core antigens-----	251
6.3.2	Group 6B: DHBV infection outcomes in ducks received ETV treatment in combination of “prime-boost” vaccines that expressed DHBV surface antigens-----	261
6.3.3	Group 6C: DHBV infection outcomes in ducks received ETV treatment in combination of “prime-boost” vaccines that expressed core antigens-----	273
6.3.4	Group 6D: DHBV infection outcomes in ducks that received ETV treatment and control vectors-----	275
6.3.5	Group 6E: DHBV infection outcomes of ducks received water treatment and control vectors-----	277
6.4	Discussion-----	282

<b>Chapter 7 Discussion</b>	
7.1	Introduction-----292
7.2	The optimisation of methods-----292
7.3	The use of CD40L expression constructs to improve immunogenicity of DNA vaccines-----295
7.4	ETV treatment in combination with “prime-boost” vaccines strategies-----301
7.5	Future directions-----306
7.6	How these studies relate to HBV infection-----311
7.7	Concluding remarks-----313
<b>References-----314</b>	

## **Table of Contents for Tables and Figures**

Table 1-1-----	3
Figure 1.1-----	4
Figure 1.2-----	7
Figure 1.3-----	11
Figure 1.4-----	14
Table 1-2-----	16
Figure 1.5-----	22
Figure 1.6-----	24
Figure 1.7-----	37
Figure 1.8-----	40
Table 2-1-----	52
Table 2-2-----	56
Table 2-3-----	57
Table 2-4-----	59
Table 2-5-----	67
Table 2-6-----	71
Table 2-7-----	84
Figure 2.1-----	89
Figure 3.1-----	92
Figure 3.2-----	96
Figure 3.3-----	97
Figure 3.4-----	98
Figure 3.5-----	102
Figure 3.6-----	103
Figure 3.7-----	105
Figure 3.8-----	108
Figure 3.9-----	109
Figure 3.10-----	112
Figure 3.11-----	113
Figure 3.12-----	114
Figure 3.13-----	115
Figure 3.14-----	116
Figure 3.15-----	119
Figure 3.16-----	123
Figure 3.17-----	125
Figure 3.18-----	127
Figure 3.19-----	128
Figure 3.20-----	130
Figure 3.21-----	132
Figure 3.22-----	133
Figure 3.23-----	136
Figure 3.24-----	138
Figure 3.25-----	140



Figure 4.1	151
Table 4-1	152
Figure 4.2	154
Figure 4.3	156
Figure 4.4	158
Figure 4.5	161
Figure 4.6	163
Table 4-2	167
Table 4-3	169
Figure 4.7	170
Figure 4.8	172
Figure 4.9	175
Table 4-4	176
Figure 4.10	177
Figure 4.11	179
Figure 4.12	182
Figure 4.13	186
Table 4-5	193
Figure 4.14	195
Figure 4.15	197
Figure 4.16	198
Figure 4.17	199

Figure 5.1	213
Table 5-1	214
Figure 5.2	215
Figure 5.3	217
Figure 5.4	219
Figure 5.5	223
Table 5-2	225
Figure 5.6	230

Table 6-1	252
Figure 6.1	253
Table 6-2	254
Table 6-3	256
Table 6-4	257
Figure 6.2	258
Figure 6.3	262
Figure 6.4	264
Figure 6.5	266
Table 6-5	268
Figure 6.6	270
Figure 6.7	278
Figure 6.8	280

## **Abstract**

The current hepatitis B virus (HBV) vaccine is of no benefit in the treatment of patients with chronic HBV infection, and current antiviral therapies which inhibit the virus polymerase are not highly effective. The ultimate aim of this Ph.D. project was to develop and assess therapeutic vaccination strategies that induce immune responses that target virus infected hepatocytes and allow successful control of chronic HBV infection. To this end, a number of vaccination strategies were tested using the duck hepatitis B virus (DHBV) model. The DHBV model provides a versatile and reproducible experimental system for testing vaccination strategies as the outcomes of DHBV infection in ducks of different ages infected with different doses of virus have been well characterised.

In initial studies described in Chapter 3, recombinant DHBV core antigen (rDHBcAg) expressed in *E. coli*, was purified and used to immunise rabbits and mice to produce specific polyclonal and monoclonal antibodies for the detection of DHBV core antigen (DHBcAg). Immuno-staining techniques using these anti-DHBcAg-specific antibodies were then optimised. Immunoperoxidase detection of DHBcAg in duck liver sections was an essential part of this analysis as it allowed comparison with detection of DHBV surface antigen (DHBsAg) and confirmation of the percentage of DHBV-infected hepatocytes. Western Blot and immunofluorescent detection of DHBcAg were also developed and optimised and then all 3 immuno-staining techniques were used in subsequent Chapters to assess the efficacy of the different vaccination strategies.

As described in Chapter 4, duck CD40L (DuCD40L), was assessed as an immunological adjuvant in a protective DNA vaccine study. In humans, CD40L acts as a co-stimulatory molecule in the CD40-signalling pathway that is involved in the activation of antigen presenting cells (APC) and the generation of humoral and cell mediated immune (CMI)

responses. In the current studies the DuCD40L cDNA sequence was cloned using mRNA from duck peripheral blood mononuclear cells (PBMC) into the expression construct, pcDNA3, to yield pcDNA3-DuCD40L. Cells and supernatants of cells transfected with pcDNA3-DuCD40L were subsequently tested for bioactivity using *in vitro* assays. The cloning and analysis of expression of the DuCD40L was performed in our laboratory by Dr Feng Feng. The DuCD40L expression construct was then co-administered intramuscularly with DNA vaccines expressing the DHBV surface and core antigens to ducks at 14 and 28 days of age. Two weeks after the second vaccination, ducks were challenged intravenously (i.v.) with  $4.5 \times 10^{10}$  DHBV genomes. Administration of the DuCD40L expression construct and the DHBV DNA vaccines in combination resulted in a 10-fold greater anti-DHBs antibody response and a significant decrease in the number of DHBV-infected hepatocytes at day 4 post-challenge (p.c.) compared to ducks that received DHBV DNA vaccines alone. Ultimately, as expected, all of the ducks successfully cleared their DHBV infection. Nevertheless, we determined that DuCD40L enhanced humoral immune responses and lead to reductions in the percentage of DHBV-infected hepatocytes following challenge.

As described in Chapter 5, the expression of DuCD40L was further assessed in a 2<sup>nd</sup> protective DNA vaccine study in 14-day-old ducks which are more susceptible to the development of persistent DHBV infection. The DuCD40L expression construct and DNA vaccines expressing the DHBV surface proteins were administered to ducks at 4 and 14 days of age. On the same day as the second vaccination, ducks were challenged i.v. with  $5 \times 10^8$  DHBV genomes, a dose of DHBV that is 500-times higher than the dose known to result in persistent DHBV infection. Unexpectedly, following DHBV challenge, no significant differences in the percentage of DHBV-infected hepatocytes or anti-DHBs antibody titres were observed between ducks receiving DHBV DNA vaccines with DuCD40L expression construct and ducks receiving DHBV DNA vaccines alone. At day 21 p.c., all ducks vaccinated with DHBV DNA vaccines with or without the DuCD40L expression construct

had successfully cleared their DHBV infection while five out of five vector control ducks developed persistent DHBV infection. Interestingly, two out of five ducks that received the DuCD40L expression construct alone also cleared their DHBV infection. The studies described in Chapters 4 and 5 suggest DuCD40L may enhance immune responses in ducks and that DuCD40L should be further investigated as an immunological adjuvant in future vaccine studies.

Finally as described in Chapter 6, a post-exposure vaccination study was performed that combined treatment with the Bristol-Myers Squibb nucleoside analogue, Entecavir (ETV), and “prime-boost” vaccination using DNA vaccines and recombinant fowl-pox virus (rFPV) strains that express DHBV surface or core alone. Previous “prime-boost” vaccination studies in the laboratory had used DNA vaccines and rFPV strains that expressed both DHBV surface and DHBV core in combination. We aimed to determine if DHBV surface antigen which generates neutralising anti-DHBs antibodies, or DHBV core antigen which generates non-neutralising anti-DHBc antibodies, could provide the essential epitopes in a DNA vaccine and “prime-boost” protocol to enable the resolution of DHBV infection. 14 day-old ducks were inoculated i.v with  $5 \times 10^8$  DHBV genomes and immediately treated with ETV (1.0mg/kg/day) for 14 days. At the same time, ducks received the “priming” DHBV DNA vaccines and 7 days later received the “boosting” vaccination with the rFPV-DHBV vaccines. The findings showed that protective humoral and CMI responses generated by “prime-boost” vaccination strategies with either DHBV surface or DHBV core alone blocked virus spread and replication and resulted in the targeting the destruction of infected hepatocytes and the resolution of DHBV infection. In contrast, ducks treated with ETV plus the control vectors showed restricted spread of DHBV infection in the liver during ETV treatment, but DHBV infection become widespread in four out of five ducks after ETV treatment was withdrawn. These findings indicate that DHBV surface and core antigen as measured in our studies are equally effective as components of our post-exposure “prime-boost” protocol. Since anti-

DHBc antibodies are non-neutralising this suggests that our “prime-boost” protocol may be generating effective CMI that were able to control DHBV infection.

The studies described in this thesis show that increasing levels of expression of DuCD40L may increase the efficacy of DNA vaccination protocols. Our novel vaccination strategy using ETV treatment in combination with “prime-boost” vaccination also suggests that DHBV surface and core antigen are both able to provide sufficient immunity to allow clearance of DHBV infection. Future studies are warranted to test other types of immunotherapy and antiviral agents to provide new directions for future therapeutic vaccination strategies for chronic HBV infection.

## **Declaration of originality and consent**

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Devin TEOH

1<sup>st</sup> November 2014

## **Publications, presentations and awards arising from this thesis**

### **Manuscripts published**

Feng, F., **C. Q. Teoh**, Q. Qiao, D. Boyle, A.R. Jilbert (2010). “The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.” Vaccine **28**(46): 7436-7443.

### **Manuscripts in preparation**

**C.Q. Teoh**, F. Feng, D. Boyle, R. Colonno, B. Baradaran, A.R. Jilbert. “Entecavir therapy combined with “prime-boost” vaccination with either duck hepatitis B virus (DHBV) surface or core are able to block virus replication and spread and target DHBV-infected hepatocytes.”

**C.Q. Teoh**, F. Feng, Q. Qiao, B. Baradaran, A.R. Jilbert. “Cloning, expression and use of a duck CD40 ligand (CD40L) DNA construct as a molecular adjuvant for duck hepatitis B virus DNA vaccines.”

**C.Q. Teoh**, F. Feng, A.R. Jilbert. “Purification of recombinant duck hepatitis B core antigen (rDHBcAg) particles for production of specific polyclonal and monoclonal antibodies against DHBcAg.”

## **Oral presentations**

**C.Q. Teoh**, F. Feng, A.R. Jilbert. Improving therapy for chronic hepatitis B infection using the duck hepatitis B virus model. Infectious Diseases Laboratories Research Seminar, IMVS, Adelaide, May, 2010.

**C.Q. Teoh**, F. Feng, A.R. Jilbert. Immune therapy for chronic hepatitis B infection. Australian Society of Microbiology (ASM) Student Award Night, Womens' and Childrens' Hospital, North Adelaide, November, 2010.

**C.Q. Teoh**, F. Feng, D. Boyle, R. Colonno, B. Baradaran, A.R. Jilbert. Entecavir therapy combined with “prime-boost” vaccination with either duck hepatitis B virus (DHBV) surface or core are able to block virus replication and spread and target DHBV-infected hepatocytes. Australian Centre for HIV and Hepatitis Virology Workshop, Novotel Barossa Valley Resort, June, 2008.

**C.Q. Teoh**, F. Feng, A.R. Jilbert. Immune therapy for chronic hepatitis B infection using duck model. The University of Adelaide, Ph.D. major review, Adelaide, September, 2008.

## **Poster presentation**

**C.Q. Teoh**, F. Feng, Q. Qiao, A.R. Jilbert. Cloning, expression and use of a duck CD40 ligand (CD40L) DNA construct as a molecular adjuvant for duck hepatitis B virus DNA vaccines. Australian Society of Microbiology (ASM), Hobart, Tasmania, June, 2011.

**C.Q. Teoh**, F. Feng, D. Boyle, R. Colonno, B. Baradaran, A.R. Jilbert. Entecavir therapy combined with “prime-boost” vaccination with either duck hepatitis B virus (DHBV) surface



or core are able to block virus replication and spread and target DHBV-infected hepatocytes.

14<sup>th</sup> International Congress of Immunology (ICI), Kobe, Japan, August, 2010.

**C.Q. Teoh**, F. Feng, Q. Qiao, A.R. Jilbert. Cloning, expression and use of a duck CD40 ligand (CD40L) DNA construct as a molecular adjuvant for duck hepatitis B virus DNA vaccines. University of Adelaide, School of Molecular and Biomedical Science, Research Symposium, Memorial Drive, Adelaide, December, 2010.

**C.Q. Teoh**, F. Feng, Q. Qiao, A.R. Jilbert. Duck CD40 ligand (CD40L) DNA construct as a molecular adjuvant for duck hepatitis B virus DNA vaccines. 5<sup>th</sup> Australian Virology Group (AVG) Meeting, Lorne, Victoria, December, 2009.

**C.Q. Teoh**, F. Feng, D. Boyle, R. Colonno, B. Baradaran, A.R. Jilbert. Entecavir therapy combined with “prime-boost” vaccination with either duck hepatitis B virus (DHBV) surface or core are able to block virus replication and spread and target DHBV-infected hepatocytes. University of Adelaide, School of Molecular and Biomedical Science, Research Symposium, National Wine Centre, Adelaide, December, 2008.

## **Awards Arising**

Travel Grant, 14<sup>th</sup> International Congress of Immunology (ICI), Kobe, Japan, 2010.

Australian Society of Microbiology (ASM) SA Branch Student Research Award, 2010.

## **Acknowledgements**

First and foremost, I would like to thank the National Health and Medical Research Council (NHMRC) of Australia for providing Ph.D. scholarship funding from the NHMRC project grant 453506 for the first 1.5 years of my Ph.D. candidature. I also wish to thank the University of Adelaide for awarding me the Faculty of Sciences Divisional Scholarship for the remaining 2 years of my Ph.D. candidature. Without this funding from the NHMRC and the University of Adelaide I would not have been able to pursue my doctorate.

I would like to express my limitless thanks to my principal supervisor, Associate Professor Allison Jilbert for the constant support of my Ph.D. study and research. Thank you so much for your patience, guidance, motivation and selfless sacrifice throughout my Ph.D. candidature. Without your supervision and constructive comments this thesis would not have been possible. Your love and kindness will always inspire me. Thank you so much, Allie.

My sincere thanks also go to my co-supervisor, Dr Feng Feng, for your continuous support, constructive comments and encouragement all these years. For everything you have done for me, particularly in the latter stages of my Ph.D. journey, I very much appreciate it. Words can never express my sincere gratitude to you. You are the best co-supervisor, Feng!

I would like to thank the previous and present members of the Hepatitis Research Laboratory, Catherine Scougall – you are a super technician to me, your broad and immense knowledge has made everything possible. Thank you so much for helping me with my duck studies and willingly listening to me all the time. Dr Behzad Baradaran, thank you so much for always making time for my animal studies even when you worked full-time at veterinary clinics. Without your help and expertise, I could not have done all these duck studies. Dr Huey-Chi Low, thanks for your unselfish assistance in my ducks studies, including naming my ducks

(haha!). Also thanks for your friendship through the good and tough times, and for all the fun times we have had in the laboratory. Dr Faseeha Noordeen, thanks for your friendship, advice and help especially during the early stages of my Ph.D. journey. Dr Michael Thorpe, thank you so much for listening and hanging out with me when I was stressed about my studies. Above all, I appreciate your friendship and I do enjoy watching Harry Potter with you! Arend Grosse, Darren Miller, Mo Li, Uwe Stroehler, Dieu Dang, Layla Zhu and other members in the Hepatitis B Research Laboratory, thanks for hours of entertainment and help whenever needed.

Special thanks to Kosta Kapellas and Ching Wong from the Australian Research Centre for Population Oral Health, The University of Adelaide for valuable discussions and performing the statistical analysis of data presented in this thesis. Thanks also to Garry Penny, John Mackrill and Alfio Comis for providing guidance and sharing valuable experience in the production of monoclonal and polyclonal antibodies. Not forgetting Dr Christopher Wong for the chats and help, particularly in printing my thesis.

I would like to thank my family: my parents Yam-Joo TEOH and Sook-Lin Saw, for raising me with love and supporting me financially and spiritually throughout my life; my siblings Ricky Teoh, Phyllis Teoh and Jess Teoh, for constant encouragement and support all these years.

Last but not least, I would like to thank Jean Ang for your constant love, patience and support, particularly during the process of pursuing my doctoral degree. Thank you for your unconditional love, you have given me every opportunity to be successful in life and courage to pursue my dream. I love you.

## Abbreviations

~	Approximately
°C	Degrees Celsius
µg	Microgram
µL	Microliter
1H.1	Monoclonal anti-pre-S/S antibodies
3TC	Lamivudine
AA	Amino acid
AB	Applied Biosystems
ADCC	Antibody-dependent cell-mediated cytotoxicity
ADV	Adefovir
ALT	Alanine aminotransferase
Amp	Ampicilin
APC	Antigen presenting cells
APV	<i>Avipoxvirus</i>
ASHV	Arctic squirrel hepatitis virus
AusDHBV	Australian strain of DHBV
bp	Base pair
BSA	Bovine serum albumin
C	Core
cccDNA	Covalently closed circular DNA
CD154	CD40 ligand
CD40L	CD40 ligand
CESC	Chicken embryonic skin cells
CHB	Chronic HBV infection
CHO	Chinese hamster ovary

CMI	Cell-mediated immunity
ConA	Concanavalin A
C-ORF	Core open reading frame
CPE	Cytopathic effect
CpG	Cytosine-phosphate-guanosine
CQT-1	Polyclonal rabbit anti-DHBc antibodies
CQT-2	Polyclonal rabbit anti-DHBc antibodies
CsCl	Caesium chloride
CSIRO	Commonwealth Scientific and Industrial Research Organisation
CTL	Cytotoxic T lymphocytes
DAB	3,3-diaminobenzidine tetrahydrochloride
DAPI	4',6-diamidino-2-phenylindole
DCs	Dendritic cells
dGTP	Deoxyguanosine triphosphate
DHBcAg	DHBV core antigen
DHBeAg	DHBV e antigen
DHBV	Duck hepatitis B virus
DMEM	Dulbecco's modified Eagle's minimal essential
dNTP	Deoxynucleotide triphosphates
dsIDNA	Double-stranded linear virus DNA
DuCD40L	Duck CD40 ligand
DW	Distilled water
<i>E. coli</i>	Escherichia coli
EAA	Ethanol: Acetic Acid
EDTA	Ethylenediaminetetraacetic acid
EEV	Extracellular enveloped virus
ELISA	The enzyme-linked immunosorbent assay

ELISPOT	The enzyme-linked immunosorbent spot assay
ETV	Entecavir
FCA	Freund's complete adjuvant
FCS	Fetal calf serum
FPV	Fowl pox virus
G	Gauge
gm	Gram
g	Centrifugal force
GSHV	Ground squirrel hepatitis virus
HBcAg	HBV core antigen
HBeAg	HBV e antigen
HBsAg	HBV surface antigen
HBSS	Hanks' balanced salt solution
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
hr	Hour
HRP	Horseradish peroxidase
i.m.	Intramuscular
i.p.	Intraperitoneal
i.v.	Intravenous
ICAM-1	Intercellular Adhesion Molecule 1
IF assay	Immuno-fluorescence assay
IFN	Interferon
IFN-g	Interferon-gamma
IFN- $\alpha$	Interferon-alfa
IFN- $\alpha$ 2A	Interferon-alfa-2a

IFN- $\beta$	Interferon-beta
Ig	Immunoglobulin
IgY	Immunoglobulin Y
IL-12	Interleukin-12
IMV	Intracellular mature virus
IMVS	Institute of Medical and Veterinary Science
IPTG	Isopropyl-beta-D-thiogalactopyranoside
ITRs	Identical inverted terminal repeats
kbp	Kilo base pair
kDa	Kilo Dalton
LB	Luria broth
LMH	Chicken hepatoma cell line
MAb	Monoclonal antibodies
MAbSA	Monoclonal Antibodies SA
MHC-I	Class I histocompatibility molecules
MHC-II	Class II histocompatibility molecules
min	Minute
mL	Millilitre
MVA	Modified vaccinia Ankara
NA	Nucleot(s)ide analogues
NC membrane	Nitrocellulose membrane
NCBI	National Center for Biotechnology Information
NDS	Normal duck serum
NEB	New England Biolabs
NGS	Normal goat serum
NHMRC	National Health and Medical Research Council
NK	Natural Killer

NK-T	Natural Killer T-cell
NLS	Nuclear localization signal
NMS	Normal mouse serum
NO	Nitric Oxide
NPC	Nuclear pore complexes
NRS	Normal rabbit serum
NSS	Normal sheep serum
NTCP	Sodium taurocholate co-transporting polypeptide
O/N	Over night
OPD	O-phenylenediamine dihydrochloride
ORF	Open reading frame
<i>p</i>	<i>p</i> -value
p.c.	Post challenge
p.f.u	Plaque forming unit
p.i.	Post-infection
PAGE	Polyacrylamide Gel Electrophoresis
PB	Phosphate buffer
PBMC	Peripheral blood mononuclear cells
PBS	Phosphate buffered saline
PBS-T	Phosphate buffered saline-Tween
PCEF	Primary chicken embryonic fibroblasts
PCR	Polymerase chain reaction
PDEF	Primary duck embryonic fibroblasts
Peg	Pegylated
Pg-RNA	Pre-genomic RNA
PHA	Phytohemagglutinin M
Pol	Polymerase



P-ORF	Polymerase open reading frame
PreC	Pre-core
pre-S/S	Pre-surface
PS	Pre-surface
PRR	Pattern recognition receptors
qPCR	Quantitative PCR
qRT-PCR	Quantitative reverse transcription PCR
R39408	Polyclonal rabbit anti-DHBc antibodies
rcDNA	Relaxed circular DNA
RE	Restriction Endonuclease
rFPV	Recombinant FPV
rFPV-124	rFPV-DHBV strains expressing DHBV core
rFPV-125	rFPV-DHBV strains expressing pre-surface antigens
rFPV-DHBc	rFPV-DHBV strains expressing DHBV core
rFPV-DHBpre-S/S	rFPV-DHBV strains expressing pre-surface antigens
rFPV-DHBV	rFPV strains expressing DHBV antigens
RGHBV	Ross' goose hepatitis B virus
rHBsAg	Recombinant HBsAg
RI DNA	Replicative intermediate DNA
RT	Room temperature
S	Surface
s.c.	Subcutaneous
SDS	Sodium dodecyl sulphate
Sec	Second
SGHBV	Snow goose hepatitis virus
SOC medium	Super optimal culture medium
S-ORF	Surface open reading frame

TCR	T cell receptor
TEMED	Tetramethylethylenediamine
Tet	Tetracycline
TFV	Tenofovir
Th1	Type I
TLR	Toll-like receptors
TNF- $\alpha$	Tumour necrosis factor-alpha
USA	United States of America
V	Volts
v.g.e.	Virus genome equivalents
WHO	World Health Organisation
WHV	Woodchuck hepatitis virus
WMHBV	Woolly monkey hepatitis B virus
X	X protein
X-ORF	X protein open reading frame